- Cardiovascular disease is the leading cause of mortality among women globally and in the US
- Using this knowledge as the motivation, Healthy Extracts, through its wholly owned subsidiary BergaMet NA, developed HERHEART(TM)
- HERHEART is derived from the bergamot fruit, richly packed with polyphenols, and is formulated specifically for women to improve heart health and perimenopausal symptoms
- Polyphenols have antioxidant and anti-inflammatory properties and are associated with improved heart health, as well as the prevention of some heart-related conditions
- Through HERHEART product, Healthy Extracts is playing a vital preventative role in the fight against cardiovascular disease among women
Cardiovascular disease is the leading cause of death in women globally – it was the cause of 39% of all deaths in 2019 (
https://ibn.fm/Rrnq8). In the US, this situation is still the same, with the Center for Disease Control noting that it accounted for 21.8% of the mortality in women of all ages, races, and origins in 2017; higher than cancer (20.7%).
More dishearteningly, pregnancy predisposes women to cardiovascular disease even decades after delivery, mainly because of risk factors such as…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at
https://ibn.fm/HYEX
About Healthy Extracts Inc.
“Live Life Young Again”
Healthy Extracts Inc. (OCTQB: HYEX) serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.
Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending.
For more information, visit:
www.healthyextractsinc.com or
www.bergametna.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Healthy Extracts Inc.
Las Vegas, Nevada
www.healthyextractsinc.com
[email protected]
720-463-1004
Corporate Communications:
InvestorBrandNetwork (“IBN”)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the
InvestorBrandNetwork.